Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481247 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
NCT00481247 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 547 participants.
The verdict
NCT00481247, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.
Interventions
- DRUG Dasatinib
- DRUG Imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2007-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481247
The ClinicalTrials.gov registry entry for NCT00481247 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00481247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481247 about?
NCT00481247 is a clinical study titled "A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia". The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment wi...
What is the current status of trial NCT00481247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2007-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00481247?
The interventions under investigation include: Dasatinib (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT00481247?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.